Paul A. Mahon Sells 6,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $225.76, for a total transaction of $1,354,560.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at $8,262,590.24. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $224.43 on Friday. The stock has a market cap of $10.53 billion, a PE ratio of 12.37 and a beta of 0.57. The company’s fifty day moving average is $225.99 and its 200 day moving average is $225.92. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $283.09. The company has a quick ratio of 8.40, a current ratio of 4.65 and a debt-to-equity ratio of 0.09.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported $5.38 EPS for the quarter, topping analysts’ consensus estimates of $5.10 by $0.28. The company had revenue of $609.40 million for the quarter, compared to analysts’ expectations of $585.82 million. United Therapeutics had a net margin of 40.82% and a return on equity of 17.10%. The firm’s revenue was up 18.1% compared to the same quarter last year. During the same quarter last year, the company earned $4.91 EPS. Research analysts anticipate that United Therapeutics Co. will post 19.03 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently added to or reduced their stakes in the business. BI Asset Management Fondsmaeglerselskab A S increased its position in shares of United Therapeutics by 204.1% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 3,302 shares of the biotechnology company’s stock valued at $740,000 after acquiring an additional 2,216 shares during the period. Pictet Asset Management SA increased its position in shares of United Therapeutics by 1.3% in the first quarter. Pictet Asset Management SA now owns 288,418 shares of the biotechnology company’s stock valued at $64,594,000 after acquiring an additional 3,766 shares during the period. DekaBank Deutsche Girozentrale increased its position in shares of United Therapeutics by 9.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 32,157 shares of the biotechnology company’s stock valued at $7,063,000 after acquiring an additional 2,797 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd increased its position in shares of United Therapeutics by 4.1% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,846 shares of the biotechnology company’s stock valued at $849,000 after acquiring an additional 152 shares during the period. Finally, KBC Group NV increased its position in shares of United Therapeutics by 6.2% in the second quarter. KBC Group NV now owns 820 shares of the biotechnology company’s stock valued at $181,000 after acquiring an additional 48 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of several analyst reports. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $290.00 to $294.00 and gave the stock an “overweight” rating in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a report on Thursday, August 3rd. Morgan Stanley dropped their price objective on shares of United Therapeutics from $318.00 to $314.00 and set an “overweight” rating for the company in a report on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and set a $308.00 price objective (up from $307.00) on shares of United Therapeutics in a report on Thursday. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $288.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.